NEPENTHE
Phase 1 Terminated
66 enrolled
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Phase 1 Terminated
35 enrolled 10 charts
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
79 enrolled 24 charts
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
Phase 1 Terminated
3 enrolled
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Phase 1 Terminated
36 enrolled 7 charts
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Phase 1 Terminated
1 enrolled
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Phase 1 Terminated
5 enrolled
Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions
Phase 1 Terminated
4 enrolled
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Phase 1 Terminated
2 enrolled 14 charts
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Phase 1 Terminated
4 enrolled
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
Phase 1 Terminated
21 enrolled
SS1
Phase 1 Terminated
14 enrolled
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
Phase 1 Terminated
5 enrolled
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
Phase 1 Terminated
SAGE
Phase 1 Terminated
50 enrolled
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
Phase 1 Terminated
12 enrolled